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OBJECTIVE—A prior genome-wide association (GWA) study in
Pima Indians identiﬁed variants within PCLO that were associ-
ated with early-onset type 2 diabetes. PCLO encodes a presyn-
aptic cytomatrix protein that functions as a Ca
2 sensor that may
be involved in insulin secretion and/or insulin action. Therefore,
PCLO was analyzed as a candidate gene for type 2 diabetes.
RESEARCH DESIGN AND METHODS—Sequencing of PCLO
identiﬁed four nonsynonymous variants and a 10–amino acid
insertion. These variants, together with 100 additional variants
identiﬁed by sequencing or chosen from databases, were geno-
typed for association analysis in the same 895 subjects analyzed
in the prior GWA study (300 case subjects with diabetes onset at
aged 25 years, 334 nondiabetic control subjects aged 45
years, and 261 discordant siblings of the case or control subjects
for within-family analyses), as well as 415 nondiabetic Pima
Indians who had been metabolically phenotyped for predictors of
diabetes. Selected variants were further genotyped in a popula-
tion-based sample of 3,501 Pima Indians.
RESULTS—Four variants were modestly associated with early-
onset type 2 diabetes in both general and within-family analyses
(P  0.004–0.04, recessive model), where the diabetes risk allele
was also nominally associated with a lower insulin-mediated
glucose disposal rate (P  0.009–0.14, recessive model) in
nondiabetic Pima Indians. However, their association with dia-
betes in the population-based sample was weaker (P  0.02–
0.20, recessive model).
CONCLUSIONS—Variation within PCLO may have a modest
effect on early-onset type 2 diabetes, possibly as a result of
reduced insulin action, but has minimal, if any, impact on
population-based risk for type 2 diabetes. Diabetes 57:3156–
3160, 2008
T
he Pima Indians of Arizona have an extremely
high prevalence of type 2 diabetes (1). Their
diabetes is characterized by obesity, dysfunction
of insulin secretion, insulin resistance (de-
creased insulin-mediated glucose disposal), and increased
rate of endogenous glucose output (2). Studies have
shown that type 2 diabetes, insulin action, acute insulin
response to glucose, and obesity are highly heritable in
this population (3–5). To identify genes that underlie the
development of type 2 diabetes in Pima Indians, we
recently completed a genome-wide association (GWA)
study using the Affymetrix 100K SNP genotyping array (6).
Two single nucleotide polymorphisms (SNPs), rs10487656
and rs10487657, that ranked among the top 1% for a
general association with early-onset type 2 diabetes (de-
ﬁned as age of onset 25 years) mapped within an intron
of the PCLO gene. PCLO is located on chromosome 7q21
and encodes for a presynaptic cytomatrix protein that
functions as a Ca
2 sensor that could potentially have a
role in insulin secretion and/or insulin action (7–10);
therefore, PCLO was analyzed as a positional and physio-
logical candidate gene for type 2 diabetes.
RESEARCH DESIGN AND METHODS
All subjects are part of our ongoing longitudinal study of the etiology of type
2 diabetes among the Gila River Indian Community in Central Arizona (1).
Diabetes status is determined by a 75-g orally administered glucose tolerance
test, with results interpreted according to the criteria of the World Health
Organization (11). All studies were approved by the institutional review board
of the National Institute of Diabetes and Digestive and Kidney Diseases. The
case/control subjects analyzed for association with early-onset type 2 diabetes
consisted of 300 case subjects (onset age 25 years, 38% male, mean
maximum BMI 38.9  8.4 kg/m
2) and 334 nondiabetic control subjects (age
45 years, 48% male, mean maximum BMI 35.4  8.0 kg/m
2). To control for
potential population stratiﬁcation, 261 additional subjects who were discor-
dant siblings of the case/control subjects were also genotyped to allow for
within-family association analyses (total of 340 discordant sib pairs from 172
informative sibships). A larger population-based sample of 3,501 full-heritage
Pima Indians consisting of 1,561 subjects with type 2 diabetes (age 37.2  12.1
years, 27% male, mean maximum BMI 38.5  8.4 kg/m
2) and 1,940 subjects
without type 2 diabetes (age 31.1  14.5 years, 46% male, mean maximum BMI
35.7  8.2 kg/m
2) was also analyzed.
For association analysis with traits that predict type 2 diabetes, 415
nondiabetic, full-heritage Pima Indians (57.9% male, age 26.7  6.2 years, BMI
34.0  7.5 kg/m
2) who had been metabolically studied as inpatients in our
clinical research center were genotyped. These nondiabetic inpatients were
determined to be healthy by medical history, physical examination, and
routine laboratory tests and were not taking medications. Oral glucose
tolerance was measured after 2–3 days on a weight-maintaining diet of mixed
composition. Blood for plasma glucose and insulin measurements was drawn
before ingesting 75 g glucose and at 30, 60, 120, and 180 min thereafter.
Subjects also received a 25-g intravenous injection of glucose over 3 min to
measure the acute insulin response (AIR). Blood samples were collected
before infusion and at 3, 4, 5, 6, 8, and 10 min after infusion for determination
of plasma glucose and insulin concentrations. AIR was calculated as the mean
increment in plasma insulin concentrations from 3 to 5 min (12). The
hyperinsulinemic-euglycemic clamp technique was used to determine basal
glucose appearance and insulin-stimulated glucose disappearance (uptake)
rates as described elsewhere (12).
SNP identiﬁcation and genotyping. To identify novel sequence variants, all
27 exons, exon-intron boundaries, 5- and 3-untranslated regions, and 2 kb of
the putative promoter region of PCLO were sequenced in DNA samples from
24 non–ﬁrst-degree related Pima Indians (12 developed diabetes with an onset
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performed using Big Dye Terminator technology (Applied Biosystems) on an
automated DNA capillary sequencer (model 3730xl; Applied Biosystems).
SNPs were genotyped by SNPlex (Applied Biosystems) following the manu-
facture’s protocol.
Expression and tissue distribution. Primers designed for the major PCLO
transcript (XM_929946; National Center for Biotechnology Information) were
used to amplify cDNA from the following human tissues: adipose, hypothal-
amus, pituitary (BD Marathon-Ready cDNA; BD Bioscience/Clontech), brain,
skeletal muscle, heart, liver, kidney, spleen, pancreas (BD Human MTC
Multiple Tissue cDNA Panels I and II; BD Bioscience/Clontech), and pancre-
atic islets (kindly provided by Dr. Lorella Marcelli at Joslin Diabetes Center).
PCR products were sequenced to conﬁrm that they encoded PCLO.
Statistical analysis. Statistical analyses were performed using version 8.0
SAS software (Cary, NC). Numeric variables are expressed as means  SE.
For continuous variables, the general estimating equation procedure was used
to adjust for the appropriate covariates and to account for the correlation
among siblings. For insulin-stimulated glucose disposal rates (M) measured
during the clamp, the covariates were age, sex, and percent body fat. For AIR
to an intravenous glucose tolerance test, the covariates were age, sex, percent
body fat, and M. The glucose disposal rates during the clamp were log
transformed before analyses to approximate a normal distribution.
In the case/control analysis for early-onset type 2 diabetes, a logistic
regression was used to adjust for sex, birth date, and sibship. For the
population-based analysis, a survival analysis (Poisson model) was used to
analyze the association of genotype with development of diabetes with
adjustment for sex and birth date; to account for sibship, this model was also
ﬁt with generalized estimating equations. To control for potential population
stratiﬁcation, the association with diabetes was also analyzed using a within-
family association test (13). We estimate that the power of the case/control
sample is 75% to detect a common (minor allele frequency 0.1) functional
allele at P  0.001 that explains 1.6% of the variance in age of onset of diabetes
for the general test and 3% of the variance for the within-family test. Similarly,
we estimate that the power of the population sample is 92% to detect an odds
ratio (OR) of 1.2 at P  0.05 for a marker with allele frequency  0.5. However,
the magnitude of the associations between several recently reported SNPs and
type 2 diabetes in Caucasians has been quite modest (ORs 1.15) (14–19). We
estimate that the power of our population-based sample to detect an OR of
1.15 is 79% for a risk allele with frequency of 0.5 and 35% for a risk allele
with frequency of 0.1. The 95% CIs for the ORs can provide a measure of the
range of effect sizes consistent with the data.
Homozygotes for the risk allele (1/1), heterozygotes (1/2), and homozy-
gotes for the protective allele (2/2) were coded to a continuous numeric
variable for genotype as 2, 1, and 0, respectively. The recessive model was
deﬁned as contrasting genotypic groups 1/1 versus 1/2  2/2. To examine
pairwise linkage disequilibrium (LD), haplotype frequencies were estimated
with the Estimating Haplotype (EH) program of Xie and Ott (http://linkage.
rockefeller.edu/ott/eh.htm), and these haplotype frequencies were used to
calculate D and r
2.
RESULTS AND DISCUSSION
Sequencing of PCLO identiﬁed variation that predicted a
10–amino acid insertion at codon 375 and 4 amino acid
substitutions at Ser4684Ala (rs2522833), Ala2742Thr
(rs976714), Val2413Ile (rs10954696), and Asp287Gly
(novel). These ﬁve variants, together with 100 additional
SNPs identiﬁed by sequencing or selected from public
databases to approximate a 5-kb dense coverage across
the PCLO locus, were genotyped for association analysis
in the same 895 early-onset type 2 diabetic case/control
subjects who were analyzed in our prior GWA study (all
105 variants are listed in online appendix Table 1 and the
LD pattern between these variants is shown in online
appendix Fig. 1 [available at http://dx.doi.org/10.2337/
db07-1800]). All of the variants were in Hardy-Weinberg
equilibrium. Four common SNPs (Ala2742Thr, Val2413Ile,
and intronic SNPs rs10487656 and rs6950504) were asso-
ciated with early-onset type 2 diabetes under both general
and within-family analyses where both recessive P values
are 0.05 (Table 1).
The 105 variants were additionally genotyped in 415 full
heritage, nondiabetic subjects who had been metabolically
phenotyped for predictors of type 2 diabetes including AIR
to an intravenous glucose bolus and insulin-stimulated
glucose disposal rate during a hyperinsulinemic-euglyce-
mic clamp. The four SNPs (Table 1) that were associated
with early-onset type 2 diabetes in the 895 case/control
subjects were also nominally associated with insulin-
stimulated glucose disposal rates (Fig. 1), where the risk
alleles for diabetes were associated with a lower insulin-
stimulated glucose disposal rate. No haplotype that pro-
vided stronger evidence for association than these single
SNPs alone was identiﬁed (data not shown).
To determine the signiﬁcance of variation in PCLO on
diabetes risk in the general Pima Indian population, the
four SNPs were further genotyped in a population-based
sample of 3,501 full-heritage Pima Indians, as deﬁned as all
subjects from our longitudinal study for whom there was
DNA available and diabetes status was known (1,561
subjects had a diagnosis of type 2 diabetes and 1,940 were
nondiabetic at their last exam). The association of these
SNPs with type 2 diabetes (as deﬁned as onset at any age)
TABLE 1
Association of four SNPs in PCLO with type 2 diabetes in a case/control sample and development of type 2 diabetes in a
population-based sample of Pima Indians
SNP
Risk allele and
frequency
Early-onset type 2 diabetes in the
case/control sample*
Development of type 2 diabetes in
the population-based sample†
General Within-family General Within-family
Ala2742Thr (rs976714) Thr (A) 0.004 0.02 0.02 0.04
(G/A) 0.50 1.83 (1.20–2.78) 1.95 (1.09–3.52) 1.12 (1.02–1.23) 1.18 (1.00–1.38)
Val2413Ile (rs10954696) Ile (A) 0.009 0.03 0.05 0.06
(G/A) 0.50 1.75 (1.15–2.67) 1.96 (1.07–3.58) 1.10 (1.00–1.21) 1.17 (0.99–1.39)
rs10487656 G 0.009 0.02 0.04 0.15
(A/G) 0.57 1.65 (1.13–2.42) 1.95 (1.08–3.51) 1.09 (1.00–1.19) 1.11 (0.96–1.28)
rs6950504 A 0.004 0.04 0.08 0.20
(G/A) 0.62 1.78 (1.19–2.65) 2.02 (1.02–4.00) 1.08 (0.99–1.17) 1.10 (0.95–1.28)
Data are adjusted P value with OR (95% CI)* and adjusted P value with hazard ratio (95% CI)†. The case/control sample is composed of 895
Pima subjects, 300 case subjects with diabetes onset age 25 years, 334 nondiabetic control subjects age 45 years, and 261 additional sibs
of either case or control group for within-family test. The population-based sample consists of 3,501 full-heritage Pima Indians and 1,561
diabetic and 1,940 nondiabetic subjects at the last visit. Most of the case/control subjects (n  715) were included in the population-based
sample. *In the case/control analysis, a logistic regression was used to adjust for sex, birth year, and family membership. †For the population
based-sample, a survival analysis (Poisson model) was applied to adjust for sex, birth year, age of last visit, age of onset for diabetes, and
family membership. All P values are for a recessive genetic model.
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1). One explanation for observing a weaker association in
the larger group of subjects is that PCLO may have a
greater role in the development of early-onset type 2
diabetes compared with diabetes at older ages (mean age
of diabetes onset is 19.2  4.5 years in the case/control
sample and 37.2  12.1 years in the population sample).
Alternatively, the associations among the case/control
subjects for early-onset type 2 diabetes and the associa-
tions with insulin action in the nondiabetic subjects may
represent false-positives. Indeed, the P values given in this
study are unadjusted for multiple comparisons, and, if
corrected for the 105 variants studied (which could be
argued to be an overcorrection due to high LD among
many of the variants), none of the P values would be
signiﬁcant. However, it remains controversial as to
whether multiple comparison correction is appropriate for
a potential physiologic candidate gene. In the present
study, we instead chose to use both a case/control general
and a within-family analysis to help restrict the number
of false-positive associations while retaining statistical
power.
It is also noteworthy that the 500 K GWA study per-
formed at the Wellcome Trust Case Control Consortium
(WTCCC) (www.wtccc.org.uk/info/summary_stats.shtml)
also identiﬁed nominal associations between eight SNPs
(with allele frequencies 0.02) in PCLO and type 2 dia-
betes (Table 2). Although these SNPs only showed a
nonsigniﬁcant trend in another 500 K GWA study of
Scandinavians (Diabetes Genetics Initiative [DGI]) (www.
broad.mit.edu/diabetes), they were signiﬁcantly associ-
ated with type 2 diabetes in a meta-analysis of subjects of
European descent (Diabetes Genetics Replication and
Meta-analysis [DIAGRAM]) (20). Five of these eight SNPs
were also genotyped in the Pima Indian case/control
sample, and several had nominal associations with type 2
diabetes (Table 2). The best SNPs in Pima Indians (listed
in Table 1) were not represented on the 500 K chip;
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FIG. 1. Mean insulin sensitivity by genotype among nondiabetic Pima Indians. Insulin-stimulated glucose uptake (mg  kg EMBS
1  min
1) was
measured by a hyperinsulinemic-euglycemic clamp with insulin infusion at physiologic concentrations. P values are given for a recessive model
for both a general association* and a within family association† and are adjusted for age, sex, percent body fat, and family membership. EMBS,
estimated metabolic body size.
TABLE 2
SNPs in PCLO associated with type 2 diabetes in the WTCCC 500 K GWA and their corresponding associations in the DGI 500 K GWA,
the DIAGRAM meta-analysis, and Pima Indians
WTCCC DGI DIAGRAM Pima Indians
SNP
Alleles
(1/2)
Case
(f1)
Control
(f1) Padd
Case
(f1)
Control
(f1) Padd Padd
Case
(f1)
Control
(f1) Padd Prec
rs34608268 A/C 0.56 0.53 0.004 0.53 0.51 0.16 — — — — —
rs2715148 C/A 0.52 0.49 0.02 0.50 0.49 0.32 0.005 0.74 0.73 0.36 0.35
rs2888019 C/T 0.52 0.49 0.02 0.51 0.49 0.34 0.003 0.75 0.70 0.07 0.15
rs1986742 T/C 0.52 0.50 0.02 0.50 0.49 0.33 0.004 — — — —
rs9690648 A/G 0.92 0.94 0.02 0.95 0.96 0.17 0.01 0.88 0.85 0.09 0.10
rs7781142 C/T 0.54 0.52 0.06 0.53 0.51 0.32 0.004 0.70 0.64 0.05 0.04
rs7799260 C/G 0.54 0.52 0.07 0.52 0.51 0.33 0.005 0.70 0.64 0.05 0.04
rs7778238 C/G 0.51 0.49 0.06 0.52 0.51 0.19 0.002 — — — —
The frequency of allele 1 (f1) for each SNP is given for case subjects (with type 2 diabetes) and control subjects in each individual population.
Frequency information was not available for the DIAGRAM meta-analysis, which combined data from the WTCCC, DGI, and FUSION studies
of subjects of European descent (ref. 20). Data for WTCCC was obtained from http://www.wtccc.org.uk/info/summary_stats.shtml. Data for
DGI was obtained from http://www.broad.mit.edu/diabetes. P values are calculated by comparison of genotypes. P values for WTCCC, DGI,
and DIAGRAM are given for an additive model (Padd). P values for the Pima Indians are given for both an additive (Padd) and a recessive
model (Prec).
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nally associated with type 2 diabetes were in high LD with
these SNPs in both Caucasians and Pima Indians (Fig. 2).
For example, rs7781142 and rs7799260 (Table 2), which
are in complete LD (D1; r
2  1) in both Caucasians (of
European descent) and Pima Indians, were in high LD with
rs976714 (Ala2742Thr) and rs10954696 (Val2413Ille) in
both Caucasians (D1; r
2  0.56) and Pima Indians
(D1; r
2  0.53) (Fig. 2).
PCLO is known to be a Ca
2 sensor in pancreatic -cells
(7), and the formation of a cAMP-GEFIIRim2Piccolo
complex in -cells is important in insulin secretion (8).
However, variants in this gene were not associated with
the AIR to a 25-g intravenous glucose bolus infusion or the
30-min insulin response to a 75-g oral glucose tolerance
test among normal glucose-tolerant Pima Indians (data not
shown). Based on our associations, we propose that PCLO
may also have a subtle role in the regulation of insulin
sensitivity in insulin-responsive tissues. As a ﬁrst step to
test this hypothesis, we have shown that PCLO is ubiqui-
tously expressed, with notable levels of expression in
insulin-responsive tissues such as adipose and liver (on-
line appendix Fig. 2). Another example of a Ca
2 sensor
having a role in modulating insulin sensitivity is the
	1-subunit of the voltage-dependent calcium channel,
which has been previously associated with insulin resis-
tance and type 2 diabetes in animal models (21) and
humans (22). The Ca
2 sensor PCLO could potentially
interact with the voltage-dependent calcium channel to
inﬂuence insulin sensitivity.
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FIG. 2. LD pattern between SNPs in Table 1* and Table 2† in Caucasians and Pima Indians. LD in Caucasians was determined by CEU data
(www.HapMap.org) using HaploView (www.broad.mit.edu/mpg/haploview). rs34608268 from Table 2 could not be included in this ﬁgure because
there was no publicly available HapMap data for this SNP, and two SNPs (rs1986742 and rs7778238) were omitted from the LD pattern in Pima
Indians because they were not genotyped in Pima Indians.
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variants with early-onset type 2 diabetes, where the asso-
ciation was further supported by quantitative trait analysis
in nondiabetic Pima Indians. However, this association
was not well substantiated in a population-based sample
of Pima Indians. We conclude that PCLO variants may
modestly increase risk for early-onset type 2 diabetes,
possibly as a result of altered insulin action, but variation
in this gene does not appear to inﬂuence the population-
based risk for developing diabetes among full-heritage
Pima Indians.
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